101 Startups
  • Sector
  • Participated in
  • Year of participation

IS-Diagnostics

  • 2010
  • Diagnostics
  • Other
The next generation of clinical diagnostics

JETA molecular

  • 2016
  • Enabling Technology
  • Other
Design, development and commercialization of noninvasive reagent and software solutions for transplant monitoring

Karveel

  • 2015
  • Therapeutics
  • Venture Challenge
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.

Khondrion

  • 2010
  • Other
  • Therapeutics
Khondrion is a clinical stage pharmaceutical company focusing on the development of treatments for mitochondrial (-related) diseases and conditions

KimerDx

  • 2013
  • Diagnostics
  • Venture Challenge
Molecular diagnostics products for chimerisme monitoring

Levels Diagnostics

  • 2019
  • Diagnostics
  • Venture Challenge
Levels Dx is using activated immune cells as biomarkers to allow an accurate diagnosis of a bacterial infection in patients. The Rapid Diagnostic Tool (RDT) will provide accurate results within minutes and is portable.

Mantis Therapeutics

  • 2016
  • Therapeutics
  • Venture Challenge
Developing an innovative targeted immunotherapy against cancer using remote controlled conditional attenuated bacteria.

MAXAM Medical

  • 2009
  • Medical Device
  • Venture Challenge
Diagnostic and treatment device for pelvic floor dysfunctions, such as prolapse, micturition, defecation and urinary and faecal incontinence

MedicalVR

  • 2020
  • Medical Device
  • Venture Challenge
MedicalVR’s PulmoVR innovation enables thoracic surgeons to cure patients with lung cancer by preventing the unnecessary removal of healthy lung tissue, resulting in a ‘lung-sparing surgical procedure’ for lung cancer.

Mercurna

  • 2016
  • Therapeutics
  • Venture Challenge
We firmly believe that everybody has the basic human right to live without the limitations of disease. Therefore, we aim to provide patients with new treatment options that add true value and allow them to break free from those limitations.